Edgewise Therapeutics (EWTX) Change in Account Payables (2020 - 2026)

Edgewise Therapeutics has reported Change in Account Payables for 7 years, with the latest figure at $1.4 million in Q1 2026.

• Quarterly Change in Account Payables fell 49.41% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.1 million (down 129.88% YoY) and the FY2025 annual result came in at $272000.0, down 84.34% from the prior year.
• Change in Account Payables grew to $1.4 million in Q1 2026 per EWTX's latest filing, from -$303000.0 in the prior quarter.
• Over five years, Change in Account Payables peaked at $2.9 million in Q1 2025 and troughed at -$2.7 million in Q2 2022.
• A 5-year average of $200588.2 and a median of $92000.0 in 2024 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2022 and 2025: Change in Account Payables jumped 1985.71% in 2022, then plunged 429.35% in 2025.
• Over 5 years, Change in Account Payables stood at $576000.0 in 2022, then plunged by 339.93% to -$1.4 million in 2023, then surged by 106.66% to $92000.0 in 2024, then slumped by 429.35% to -$303000.0 in 2025, then surged by 577.23% to $1.4 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered $1.4 million, -$303000.0, and -$2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.